Alginic Acid: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: February 20, 2026🚩 Report this page

Alginic Acid

Other Drugs For Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)

GB MHRA

Drug class: Other Drugs For Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
Availability: See label
Markets covered: 1
Products on record: 1

A02BXOther Drugs For Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)

Overview

Alginic Acid is an active pharmaceutical ingredient in the Other Drugs For Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) group (A02BX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	February 20, 2026

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised February 20, 2026[1]

Symptomatic treatment of complaints resulting from gastro-oesophageal reflux and hyperacidity, such as regurgitation and heartburn.

How to take

Sources & citations

[1]MHRA (UK) · PL000100514 · revised February 20, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised February 20, 2026[1]

Immune System Disorders:
Hypersensitivity reactions have very rarely been reported. Clinical symptoms may include rash, pruritus, urticaria, angioedema dyspnea and anaphylaxis.
Metabolism and nutrition disorders:
Prolonged use of high doses may possibly result in hypermagnesaemia or hypercalcaemia and alkalosis (GI symptoms such as nausea and vomiting, fatigue, confusion, polyuria, polydypsia, dehydration), particularly in patients with impaired renal function.
Prolonged use of high doses of calcium carbonate with milk may lead to Burnett syndrome (milkalkali syndrome).
Gastrointestinal disorders:
Nausea, vomiting, stomach discomfort, constipation and diarrhoea may occur.
Musculoskeletal and Connective Tissue Disorders:
Muscular weakness may occur. 9): Gastrointestinal Disorders: Ageusia may occur in the context of milk-alkali syndrome.
General Disorders and Administration Site Conditions:
Calcinosis and asthenia may occur in the context of milk-alkali syndrome.
Nervous System Disorders:
Headache may occur in the context of milk-alkali syndrome.
Renal and Urinary Disorders:
Azotemia may occur in the context of milk-alkali syndrome. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised February 20, 2026[1]

Prolonged use should be avoided. If the symptoms persist or only partly disappear, further medical advice should be sought. As with other antacids, Rennie Extra tablets may mask a malignancy in the stomach. Rennie Extra tablets should not be used in the following cases: Hypercalciuria In general, caution should be exercised in patients with impaired renal function.
If Rennie Extra tablets are used in such patients, plasma concentrations of calcium, phosphate and magnesium should be monitored regularly. In general calcium containing antacids should be carefully administered in patients with constipation, haemorrhoids and sarcoidosis.
Prolonged use of high doses may result in undesirable side-effects such as hypercalcaemia, magnesaemia and the milk alkali syndrome, particularly in patients suffering from renal insufficiency. The product should not be taken with large amounts of milk or dairy products.
Prolonged use increases the risk of formation of renal calculi. In the literature a possible relationship between calcium carbonate and appendicitis, gastrointestinal haemorrhage, intestinal blockage, or oedema has been reported in single cases.
7% of the WHO recommended maximum daily intake of 2g sodium for an adult. 22 mg glucose (including from dextrates) per tablet, which should be taken into account in patients with diabetes. Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
If symptoms persist after fourteen days, the clinical situation should be reviewed by a healthcare professional.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations